泽布替尼联合维奈克拉治疗伴或不伴del(17p)/TP53突变的初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤:SEQUOIA研究D臂结果
SEQUOIA研究D臂为非随机队列,评估泽布替尼联合维奈克拉治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL),入组114例患者(66例伴TP53异常,47例不伴,1例TP53结果缺失)。中位随访31.2个月,24个月无进展生存率估计为92%(95%CI 85%至96%),意向治疗人群外周血不可检测微小残留病(uMRD)率达59%。结论:该联合方案在初治CLL/SLL中显示显著疗效和良好安全性,无论是否存在TP53异常。
要点
- SEQUOIA研究D臂中泽布替尼联合维奈克拉治疗初治CLL/SLL,24个月无进展生存率估计为92%(95%CI 85%至96%)。
- 意向治疗人群外周血uMRD率为59%,中位随访31.2个月时75%患者仍在泽布替尼单药治疗。
- 最常见任何级别治疗中出现的不良事件(TEAE)为COVID-19(54%)、腹泻(41%)、挫伤(32%)和恶心(30%)。
核心结论
- 泽布替尼联合维奈克拉在初治CLL/SLL患者中显示出显著疗效和良好安全性,无论是否存在TP53异常疾病。
研究设计与样本
- SEQUOIA研究D臂为非随机队列,入组年龄≥65岁或18-64岁伴合并症的初治CLL/SLL患者。
- 患者自第1周期接受泽布替尼,自第4周期(剂量递增)至第28周期接受维奈克拉,随后持续泽布替尼单药治疗直至疾病进展(PD)、不可接受毒性或满足uMRD指导的停药标准。
- 2019年11月至2022年7月共入组114例患者:66例(58%)伴TP53异常,47例(41%)不伴TP53异常,1例TP53结果缺失。
主要发现
- 中位随访31.2个月时,85例(75%)患者仍在泽布替尼单药治疗,29例(25%)因不良事件、uMRD指导停药标准、PD或其他原因停用泽布替尼。
- 意向治疗人群中59%的患者达到外周血uMRD。
- 24个月无进展生存率估计为92%(95%CI 85%至96%)。
- 最常见任何级别TEAE为COVID-19(54%)、腹泻(41%)、挫伤(32%)和恶心(30%)。
- 最常见≥3级TEAE为中性粒细胞减少(17%)、高血压(10%)、腹泻(6%)和中性粒细胞计数降低(6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation (TP53mut) comprised a small percentage of study populations or were excluded entirely. The purpose of the SEQUOIA Arm D cohort was to evaluate the combination of zanubrutinib + venetoclax in treatment-naïve (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population of patients with TP53-aberrant disease. PATIENTS AND METHODS: Arm D is a nonrandomized cohort of patients aged 65 years and older (or 18-64 years with comorbidities). Patients received zanubrutinib from cycle 1 and venetoclax from cycle 4 (ramp-up) to cycle 28, followed by continuous zanubrutinib monotherapy until progressive disease (PD), unacceptable toxicity, or meeting undetectable minimal residual disease (uMRD)-guided stopping criteria. RESULTS: Between November 2019 and July 2022, 114 patients were enrolled: 66 (58%) with TP53-aberrant disease, 47 (41%) without TP53-aberrant disease, and 1 with missing TP53 results. At a median follow-up of 31.2 months, 85 patients (75%) remained on zanubrutinib monotherapy; 29 patients (25%) discontinued zanubrutinib because of adverse event, uMRD-guided stopping criteria, PD, or other. In the intention-to-treat population, 59% of patients achieved peripheral blood uMRD. The 24-month progression-free survival estimate was 92% (95% CI, 85% to 96%). The most common any-grade treatment-emergent AEs (TEAEs) were COVID-19 (54%), diarrhea (41%), contusion (32%), and nausea (30%). The most common grade ≥3 TEAEs were neutropenia (17%), hypertension (10%), diarrhea (6%), and decreased neutrophil count (6%). CONCLUSION: Zanubrutinib + venetoclax demonstrated impressive efficacy and a favorable safety profile in patients with TN CLL/SLL, regardless of the presence of TP53-aberrant disease.
引用
- Shadman M, Munir T, Ma S, et al. Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. J Clin Oncol. 2025. PMID: 40448577. doi:10.1200/JCO-25-00758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。